Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 13, 2016 2:48 PM ET


Company Overview of Omthera Pharmaceuticals, Inc.

Company Overview

Omthera Pharmaceuticals, Inc. develops therapies for the treatment of dyslipidemia and cardiovascular diseases. Its products include Epanova, an Omega 3 fatty acid that has completed Phase III clinical studies to treat patients with triglycerides. The company has a license agreement with Chrysalis Pharma AG to develop and commercialize Epanova; and an agreement with BioVectra Inc. for the manufacture of the active pharmaceutical ingredient for Epanova. Omthera Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Princeton, New Jersey. As of July 18, 2013, Omthera Pharmaceuticals, Inc. operates as a subsidiary of AstraZeneca LP.

707 State Road

Princeton, NJ 08540

United States

Founded in 2008

14 Employees





Key Executives for Omthera Pharmaceuticals, Inc.

Chairman and President
Co-Founder and Chief Medical Officer
Age: 58
Chief Financial Officer and Vice President of Finance
Financial Controller
Vice President of CMC/Manufacturing
Compensation as of Fiscal Year 2015.

Omthera Pharmaceuticals, Inc. Key Developments

Ligand Pharmaceuticals Inc. Inks Research and Licensing Pact with Omthera Pharmaceuticals, Inc

Ligand Pharmaceuticals Inc. announced that it has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals, Inc. for the development of products to treat dyslipidemia, including hypertriglyceridemia. The research collaboration will target the development of novel products that utilize the proprietary Ligand-developed LTP Technology to improve lipid-lowering activity of certain omega-3 fatty acids. Under the terms of the agreement, Ligand will be eligible to receive payments of up to $44.5 million upon the achievement of specific milestones, as well as tiered royalties ranging from mid to high single digits of net sales. Omthera is solely responsible for all research and clinical development costs as well as commercialization of any product(s) derived from this collaboration.

Omthera Enters into Research and Licensing Agreement with Ligand Pharmaceuticals

Omthera (part of AstraZeneca, UK) and Ligand Pharmaceuticals have entered into a licensing agreement and research collaboration focused on the development of novel dyslipidaemia treatments utilising Ligand's LTP TECHNOLOGY to improve lipid-lowering activity of certain omega-3 fatty acids. As per the agreement, Omthera will take on the responsibility for the search and development costs. It would additionally be responsible for the commercialising of any resulting products. In turn, Ligand will be liable to milestone payments of up to USD 44.5 million and tiered royalties on net sales of mid-to-high single digits.

Amarin Pharmaceuticals Ireland Limited Files Complaint Against Omthera Pharmaceuticals, Inc. and Astrazeneca Pharmaceuticals LP

Amarin Pharmaceuticals Ireland Limited announced that on March 4, 2014, the company, filed a complaint in the United States District Court for the District of Delaware against Omthera Pharmaceuticals, Inc. and AstraZeneca Pharmaceuticals LP. The suit seeks injunctive relief and monetary damages for infringement of Amarin's U.S. Patent No. 8,663,662, which was issued by the United States Patent and Trademark Office. The complaint alleges infringement of the Patent arising from the expected launch of Epanova in the United States. The Patent covers methods of lowering triglycerides by administering a pharmaceutical composition that includes amounts of EPA as free acid, and no more than about 30% DHA. Amarin intends to pursue this litigation vigorously and aggressively protect its intellectual property rights.

Similar Private Companies By Industry

Company Name Region
Bodyonics Ltd. United States
Mithridion, Inc. United States
Alternecare Health Products, Inc. United States
Ozelle Pharmaceuticals Inc. United States
Hisamitsu America Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Omthera Pharmaceuticals, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at